Alliancebernstein L.P. Trevi Therapeutics, Inc. Transaction History
Alliancebernstein L.P.
- $280 Billion
- Q4 2024
A detailed history of Alliancebernstein L.P. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 15,440 shares of TRVI stock, worth $104,528. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,440
Previous 15,440
-0.0%
Holding current value
$104,528
Previous $51,000
27.45%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding TRVI
# of Institutions
114Shares Held
77.6MCall Options Held
218KPut Options Held
182K-
Nea Management Company, LLC Timonium, MD11.4MShares$77 Million3.46% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.7MShares$72.2 Million2.72% of portfolio
-
Viking Global Investors LP4.4MShares$29.8 Million0.06% of portfolio
-
Rubric Capital Management LP New York, NY4.21MShares$28.5 Million0.3% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.15MShares$28.1 Million0.04% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $395M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...